|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Ghoneim MA, Abdel-Latif M, el-Mekresh M,
et al: Radical cystectomy for carcinoma of the bladder: 2,720
consecutive cases 5 years later. J Urol. 180:121–127.
2008.PubMed/NCBI
|
|
3
|
Vishnu P, Mathew J and Tan WW: Current
therapeutic strategies for invasive and metastatic bladder cancer.
Onco Targets Ther. 4:97–113. 2011.PubMed/NCBI
|
|
4
|
van Beijnum JR, Buurman WA and Griffioen
AW: Convergence and amplification of toll-like receptor (TLR) and
receptor for advanced glycation end products (RAGE) signaling
pathways via high mobility group B1 (HMGB1). Angiogenesis.
11:91–99. 2008.PubMed/NCBI
|
|
5
|
Zhang J, McCauley MJ, Maher LJ III, et al:
Mechanism of DNA flexibility enhancement by HMGB proteins. Nucleic
Acids Res. 37:1107–1114. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stros M, Polanská E, Struncová S and
Pospísilová S: HMGB1 and HMGB2 proteins up-regulate cellular
expression of human topoisome rase IIalpha. Nucleic Acids Res.
37:2070–2086. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krynetskaia NF, Phadke MS, Jadhav SH and
Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3
trigger cellular response to chemotherapy-induced DNA damage. Mol
Cancer Ther. 8:864–872. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Balani P, Boulaire J, Zhao Y, et al: High
mobility group box2 promoter-controlled suicide gene expression
enables targeted glioblastoma treatment. Mol Ther. 17:1003–1011.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Naglova H and Bucova M: HMGB1 and its
physiological and pathological roles. Bratisl Lek Listy.
113:163–171. 2012.PubMed/NCBI
|
|
10
|
Franklin S, Chen H, Mitchell-Jordan S, et
al: Quantitative analysis of the chromatin proteome in disease
reveals remodeling principles and identifies high mobility group
protein b2 as a regulator of hypertrophic growth. Mol Cell
Proteomics. 11:M111.0142582012. View Article : Google Scholar
|
|
11
|
Dong Xda E, Ito N, Lotze MT, et al: High
mobility group box I (HMGB1) release from tumor cells after
treatment: implications for development of targeted
chemoimmunotherapy. J Immunother. 30:596–606. 2007.PubMed/NCBI
|
|
12
|
Yao X, Zhao G, Yang H, et al:
Overexpression of high-mobility group box 1 correlates with tumor
progression and poor prognosis in human colorectal carcinoma. J
Cancer Res Clin Oncol. 136:677–684. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen X, Hong L, Sun H, et al: The
expression of high-mobility group protein box 1 correlates with the
progression of non-small cell lung cancer. Oncol Rep. 22:535–539.
2009.PubMed/NCBI
|
|
14
|
Kostova N, Zlateva S, Ugrinova I and
Pasheva E: The expression of HMGB1 protein and its receptor RAGE in
human malignant tumors. Mol Cell Biochem. 337:251–258. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma A, Ray R and Rajeswari MR:
Overexpression of high mobility group (HMG) B1 and B2 proteins
directly correlates with the progression of squamous cell carcinoma
in skin. Cancer Invest. 26:843–851. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gnanasekar M, Thirugnanam S and Ramaswamy
K: Short hairpin RNA (shRNA) constructs targeting high mobility
group box-1 (HMGB1) expression leads to inhibition of prostate
cancer cell survival and apoptosis. Int J Oncol. 34:425–431.
2009.PubMed/NCBI
|
|
17
|
Song B, Song WG, Li ZJ, et al: Effect of
HMGB1 silencing on cell proliferation, invasion and apoptosis of
MGC-803 gastric cancer cells. Cell Biochem Funct. 30:11–17. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rhodes DR, Yu J, Shanker K, et al:
Large-scale meta-analysis of cancer microarray data identifies
common transcriptional profiles of neoplastic transformation and
progression. Proc Natl Acad Sci USA. 101:9309–9314. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiao Y, Wang HC and Fan SJ: Growth
suppression and radio-sensitivity increase by HMGB1 in breast
cancer. Acta Pharmacol Sin. 28:1957–1967. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1 and cancer. Biochim Biophys Acta.
1799:131–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sitohy B, Nagy J and Dvorak H:
Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer
Res. 72:1909–1914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ajili F, Kacem M, Tounsi H, et al:
Prognostic impact of angio-genesis in nonmuscle invasive bladder
cancer as defined by microvessel density after immunohistochemical
staining for CD34. Ultrastruct Pathol. 36:336–342. 2012. View Article : Google Scholar
|
|
23
|
Deniz H, Karakök M, Yagci F and Güldür ME:
Evaluation of relationship between HIF-1alpha immunoreactivity and
stage, grade, angiogenic profile and proliferative index in bladder
urothelial carcinomas. Int Urol Nephrol. 42:103–107. 2012.
View Article : Google Scholar
|
|
24
|
Yang GL, Zhang LH, Bo JJ, et al: Increased
expression of HMGB1 is associated with poor prognosis in human
bladder cancer. J Surg Oncol. 106:57–61. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang D, Kang R, Cheh CW, et al: HMGB1
release and redox regulates autophagy and apoptosis in cancer
cells. Oncogene. 29:5299–5310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Todorova J and Pasheva E: High mobility
group B1 protein interacts with its receptor RAGE in tumor cells
but not in normal tissues. Oncol Lett. 3:214–218. 2012.PubMed/NCBI
|
|
27
|
Pusterla T, de Marchis F, Palumbo R and
Bianchi ME: High mobility group B2 is secreted by myeloid cells and
has mitogenic and chemoattractant activities similar to high
mobility group B1. Autoimmunity. 42:308–310. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Le XF, Lammayot A, Gold D, et al: Genes
affecting the cell cycle, growth, maintenance, and drug sensitivity
are preferentially regulated by anti-HER2 antibody through
phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem.
280:2092–2104. 2005.
|
|
29
|
van Beijnum JR, Nowak-Sliwinska P, van den
Boezem E, et al: Tumor angiogenesis is enforced by autocrine
regulation of high-mobility group box 1. Oncogene. Mar 5–2012.(Epub
ahead of print). View Article : Google Scholar
|
|
30
|
Sachdev U, Cui X, Hong G, et al: High
mobility group box 1 promotes endothelial cell angiogenic behavior
in vitro and improves muscle perfusion in vivo in response to
ischemic injury. J Vasc Surg. 55:180–191. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Urquidi V, Goodison S, Kim J, et al:
Vascular endothelial growth factor, carbonic anhydrase 9, and
angiogenin as urinary bio markers for bladder cancer detection.
Urology. 79:1185.e1–6. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chavakis E, Hain A, Vinci M, et al:
High-mobility group box 1 activates integrin-dependent homing of
endothelial progenitor cells. Circ Res. 100:204–212. 2007.
View Article : Google Scholar : PubMed/NCBI
|
